MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care

Recruiting

Phase 3

Magnesium vs. AmiodaroneMAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care

Sponsor:

Sunnybrook Health Sciences Centre

Code:

NCT05287191

Conditions

Atrial Fibrillation New Onset

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Magnesium sulfate and then Digoxin

Amiodarone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Sunnybrook Health Sciences Centre on 2024-04-25.